Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | steroid-5-alpha-reductase, alpha polypeptide 1 (3-oxo-5 alpha-steroid delta 4-dehydrogenase alpha 1) | Starlite/ChEMBL | References |
Homo sapiens | steroid-5-alpha-reductase, alpha polypeptide 2 (3-oxo-5 alpha-steroid delta 4-dehydrogenase alpha 2) | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Plasmodium falciparum | 3-oxo-5-alpha-steroid 4-dehydrogenase, putative | steroid-5-alpha-reductase, alpha polypeptide 1 (3-oxo-5 alpha-steroid delta 4-dehydrogenase alpha 1) | 259 aa | 254 aa | 25.6 % |
Brugia malayi | Synaptic glycoprotein SC2 | steroid-5-alpha-reductase, alpha polypeptide 2 (3-oxo-5 alpha-steroid delta 4-dehydrogenase alpha 2) | 254 aa | 208 aa | 28.9 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Mycobacterium tuberculosis | Dihydrofolate reductase DfrA (DHFR) (tetrahydrofolate dehydrogenase) | 0.2278 | 1 | 1 |
Mycobacterium ulcerans | thymidylate synthase | 0.0159 | 0.0267 | 0.0267 |
Leishmania major | dihydrofolate reductase-thymidylate synthase | 0.103 | 0.4267 | 1 |
Mycobacterium ulcerans | hypothetical protein | 0.0377 | 0.127 | 0.127 |
Brugia malayi | thymidylate synthase | 0.0159 | 0.0267 | 0.0267 |
Loa Loa (eye worm) | hypothetical protein | 0.0377 | 0.127 | 0.127 |
Trypanosoma cruzi | 3-oxo-5-alpha-steroid 4-dehydrogenase, putative | 0.0377 | 0.127 | 0.2977 |
Leishmania major | 3-oxo-5-alpha-steroid 4-dehydrogenase-like protein | 0.0377 | 0.127 | 0.2977 |
Echinococcus multilocularis | dihydrofolate reductase | 0.2278 | 1 | 1 |
Echinococcus multilocularis | thymidylate synthase | 0.0159 | 0.0267 | 0.0267 |
Plasmodium vivax | bifunctional dihydrofolate reductase-thymidylate synthase, putative | 0.103 | 0.4267 | 1 |
Brugia malayi | 3-oxo-5-alpha-steroid 4-dehydrogenase 1 | 0.0377 | 0.127 | 0.127 |
Trypanosoma cruzi | dihydrofolate reductase-thymidylate synthase | 0.103 | 0.4267 | 1 |
Mycobacterium leprae | DIHYDROFOLATE REDUCTASE DFRA (DHFR) (TETRAHYDROFOLATE DEHYDROGENASE) | 0.2278 | 1 | 1 |
Mycobacterium ulcerans | dihydrofolate reductase DfrA | 0.2278 | 1 | 1 |
Plasmodium falciparum | bifunctional dihydrofolate reductase-thymidylate synthase | 0.103 | 0.4267 | 1 |
Chlamydia trachomatis | dihydrofolate reductase | 0.2278 | 1 | 0.5 |
Schistosoma mansoni | bifunctional dihydrofolate reductase-thymidylate synthase | 0.0159 | 0.0267 | 0.0267 |
Entamoeba histolytica | steroid 5-alpha reductase, putative | 0.0377 | 0.127 | 0.5 |
Trypanosoma brucei | dihydrofolate reductase-thymidylate synthase | 0.103 | 0.4267 | 1 |
Mycobacterium leprae | PROBABLE THYMIDYLATE SYNTHASE THYA (TS) (TSASE) | 0.0159 | 0.0267 | 0.0267 |
Trichomonas vaginalis | 3-oxo-5-alpha-steroid 4-dehydrogenase, putative | 0.0377 | 0.127 | 1 |
Schistosoma mansoni | dihydrofolate reductase | 0.2278 | 1 | 1 |
Trichomonas vaginalis | 3-oxo-5-alpha-steroid 4-dehydrogenase, putative | 0.0377 | 0.127 | 1 |
Treponema pallidum | folylpolyglutamate synthetase (folC) | 0.0101 | 0 | 0.5 |
Brugia malayi | Dihydrofolate reductase | 0.2278 | 1 | 1 |
Echinococcus granulosus | dihydrofolate reductase | 0.2278 | 1 | 1 |
Trichomonas vaginalis | 3-oxo-5-alpha-steroid 4-dehydrogenase, putative | 0.0377 | 0.127 | 1 |
Onchocerca volvulus | 0.0159 | 0.0267 | 1 | |
Loa Loa (eye worm) | dihydrofolate reductase | 0.2278 | 1 | 1 |
Echinococcus granulosus | thymidylate synthase | 0.0159 | 0.0267 | 0.0267 |
Toxoplasma gondii | bifunctional dihydrofolate reductase-thymidylate synthase | 0.103 | 0.4267 | 1 |
Loa Loa (eye worm) | thymidylate synthase | 0.0159 | 0.0267 | 0.0267 |
Toxoplasma gondii | 3-oxo-5-alpha-steroid 4-dehydrogenase | 0.0377 | 0.127 | 0.2977 |
Trypanosoma cruzi | 3-oxo-5-alpha-steroid 4-dehydrogenase, putative | 0.0377 | 0.127 | 0.2977 |
Trypanosoma brucei | 3-oxo-5-alpha-steroid 4-dehydrogenase-like, putative | 0.0377 | 0.127 | 0.2977 |
Mycobacterium tuberculosis | Probable thymidylate synthase ThyA (ts) (TSASE) | 0.0159 | 0.0267 | 0.0267 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | uM | Inhibition of Cytochrome P450 17 of human testicular microsome at 125 uM progesterone; No inhibition | ChEMBL. | 11063622 |
IC50 (binding) | uM | Inhibition of Cytochrome P450 17 from rat testicular microsome at 125 uM progesterone; No inhibition | ChEMBL. | 11063622 |
IC50 (binding) | 0 uM | Inhibition of Cytochrome P450 17 from rat testicular microsome at 125 uM progesterone; No inhibition | ChEMBL. | 11063622 |
IC50 (binding) | 0 uM | Inhibition of Cytochrome P450 17 of human testicular microsome at 125 uM progesterone; No inhibition | ChEMBL. | 11063622 |
IC50 (binding) | = 0.43 uM | Evaluated for the inhibitory activity against human steroid 5-alpha-reductase type 2 from human BPH tissue at 210 nM of testosterone | ChEMBL. | 11063622 |
IC50 (binding) | = 0.43 uM | Evaluated for the inhibitory activity against human steroid 5-alpha-reductase type 2 from human BPH tissue at 210 nM of testosterone | ChEMBL. | 11063622 |
IC50 (binding) | = 0.86 uM | Inhibition of Human steroid 5-alpha-reductase type II expressed in HEK293 cells | ChEMBL. | 11063622 |
IC50 (binding) | = 0.86 uM | Inhibition of Human steroid 5-alpha-reductase type II expressed in HEK293 cells | ChEMBL. | 11063622 |
IC50 (binding) | = 0.9 uM | Evaluated for the inhibitory activity against human steroid 5-alpha-reductase type I in human DU-145 cell assay at 5 nM of androstenedione | ChEMBL. | 11063622 |
IC50 (binding) | = 0.9 uM | Evaluated for the inhibitory activity against human steroid 5-alpha-reductase type I in human DU-145 cell assay at 5 nM of androstenedione | ChEMBL. | 11063622 |
IC50 (binding) | = 2.9 uM | Inhibition of Human steroid 5-alpha-reductase type I expressed in HEK293 cells | ChEMBL. | 11063622 |
IC50 (binding) | = 2.9 uM | Inhibition of Human steroid 5-alpha-reductase type I expressed in HEK293 cells | ChEMBL. | 11063622 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.